Abstract
Degradation of extracellular matrix is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all matrix components. Elevated levels of distinct MMPs can be detected in tumor tissue or serum of patients with advanced cancer, and their role as prognostic indicators in cancer has been widely examined. In addition, therapeutic intervention in tumor growth and invasion based on inhibition of MMP activity is under intensive investigation and several MMP inhibitors (MMPIs) are in clinical cancer trials. Even though results of the first clinical trials in advanced cancer have been mostly disappointing, there are also positive results. Recent observations show, that certain MMPs limit tumor growth. Therefore, identification of proper MMPs for therapeutic intervention with array-based molecular classifications of tumors and targeting these with more specific MMPIs in combination with conventional chemotherapy is expected to provide a feasible approach for cancer therapy. MMPIs represent a totally different therapeutic modality from proven anti-cancer drugs and thus traditional approaches to evaluate drug efficiency cannot be used without modification. In this review, we discuss the current view on the feasibility of MMPs as targets for therapeutic intervention in cancer.
Keywords: mmp, mmpi, cancer, prognosis, angiogenesis, survival
Current Cancer Drug Targets
Title: Matrix Metalloproteinases as Therapeutic Targets in Cancer
Volume: 5 Issue: 3
Author(s): Pia Vihinen, Risto Ala-aho and Veli-Matti Kahari
Affiliation:
Keywords: mmp, mmpi, cancer, prognosis, angiogenesis, survival
Abstract: Degradation of extracellular matrix is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all matrix components. Elevated levels of distinct MMPs can be detected in tumor tissue or serum of patients with advanced cancer, and their role as prognostic indicators in cancer has been widely examined. In addition, therapeutic intervention in tumor growth and invasion based on inhibition of MMP activity is under intensive investigation and several MMP inhibitors (MMPIs) are in clinical cancer trials. Even though results of the first clinical trials in advanced cancer have been mostly disappointing, there are also positive results. Recent observations show, that certain MMPs limit tumor growth. Therefore, identification of proper MMPs for therapeutic intervention with array-based molecular classifications of tumors and targeting these with more specific MMPIs in combination with conventional chemotherapy is expected to provide a feasible approach for cancer therapy. MMPIs represent a totally different therapeutic modality from proven anti-cancer drugs and thus traditional approaches to evaluate drug efficiency cannot be used without modification. In this review, we discuss the current view on the feasibility of MMPs as targets for therapeutic intervention in cancer.
Export Options
About this article
Cite this article as:
Vihinen Pia, Ala-aho Risto and Kahari Veli-Matti, Matrix Metalloproteinases as Therapeutic Targets in Cancer, Current Cancer Drug Targets 2005; 5 (3) . https://dx.doi.org/10.2174/1568009053765799
DOI https://dx.doi.org/10.2174/1568009053765799 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heparanase Inhibitors Facilitate the Assembly of the Basement Membrane in Artificial Skin
Current Tissue Engineering (Discontinued) Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Design and Green Synthesis of Thieno[2,3-d]pyrimidine Analogues as Potential Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences DNA-Electrochemical Biosensors: AFM Surface Characterisation and Application to Detection of In Situ Oxidative Damage to DNA
Combinatorial Chemistry & High Throughput Screening Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety Prostate Cancer Prevention by Silibinin
Current Cancer Drug Targets No Effect of Metformin on Ovarian Cancer Survival: A Systematic Review and Meta-Analysis of Cohort Studies
Current Pharmaceutical Design Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Oral Drug Delivery Systems for Ulcerative Colitis Therapy: A Comparative Study with Microparticles and Nanoparticles
Current Cancer Drug Targets A Role for Tumor Suppressor Protein p53 in the Fidelity of DNA Synthesis and Resistance Towards Nucleoside Analogs
Current Cancer Therapy Reviews Synthesis and In vitro/In vivo Characterization of Raloxifene Grafted Poly(Styrene Maleic Acid)-Poly(Amide-Ether-Ester-Imide) Micelles for Targeted Delivery of Docetaxel in G Protein-Coupled Estrogen Receptor Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Bioprecursor Prodrugs: Molecular Modification of the Active Principle
Mini-Reviews in Medicinal Chemistry The Role of miRNAs in Plasma Cell Dyscrasias
MicroRNA Template Dependent Human DNA Polymerases
Current Topics in Medicinal Chemistry High-accuracy Automated Diagnosis of Parkinson's Disease
Current Medical Imaging PET Imaging for Gene & Cell Therapy
Current Gene Therapy The Use of 68Ga-DOTA-(Tyr3)-Octreotate PET/CT for Improved Target Definition in Radiotherapy Treatment Planning of Meningiomas – A Case Report
Current Radiopharmaceuticals Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis
Current Drug Targets Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Current Signal Transduction Therapy